In my June 3, 2025 post, I disclose my rationale for initiating a 500 share position in Howard Hughes Holdings (HHH) in one of the 'Core' accounts in the FFJ Portfolio. I subsequently increased my exposure to 1000 shares and disclosed this in my June 9, 2025 post; my average cost is ~$67.90. In this [...]
I last reviewed Exxon Mobil (XOM) in this August 2, 2024 post at which time the most current financial information was for Q2 and YTD 2024. In addition, it had relatively recently completed the Pioneer Natural Resources (Pioneer) acquisition. On August 1, 2025, XOM released its Q2 and YTD2025 results thus prompting me to revisit [...]
In my August 17, 2022 Chevron (CVX) post, I touch upon why I think the demise of oil and gas is overblown. At the time, CVX's share price was ~$154. The share price has exhibited wild swings in the past 3 years with the current share price being ~$150 as I compose this post on [...]
I last reviewed S&P Global (SPGI) in this April 30, 2025 post at which time the current share price was ~$492 and the most current quarterly financial information was for Q1 2025. My suggestion was that investors acquire shares in great companies during periods of turmoil. Now that SPGI has released Q2 and FY2025 results [...]
This FFJ Portfolio - July 2025 report is a high-level recap of my activity during the month. In an environment where much does not make sense, it is worthwhile to be prudent. In my FFJ Portfolio - June 2025 report, I note investor willingness to borrow for investment purposes (Debit Balances in Customers' Securities Margin [...]
Despite being a loyal Canadian, I have very little desire to invest in Canadian companies. My reasoning is that I think I can generate superior long-term total investment returns from US companies. Secondly, most Canadian listed companies do not satisfy my risk tolerance. This is why I have made a conscious decision to limit my [...]
In my June 27, 2025 Why I Added Accenture To The FFJ Portfolio post, I disclose a new Accenture (ACN) position. Following my initial purchase, I have increased my exposure in keeping with the Final Thoughts expressed in my prior post. ACN is a new holding and my current exposure is only 200 shares. It [...]
I last reviewed CME Group Inc. (CME) in this April 26, 2025 post at which time the Q1 2025 results were the most current. With the release of the Q2 2025 financial results on July 23, 2025, I revisit this existing holding. Business Overview CME operates a derivatives marketplace which offers a range of futures [...]
On June 12, 2023, Nasdaq (NDAQ) announced its intent to acquire Adenza from Thoma Bravo for ~$10.5B in cash and stock. When making this announcement, it made deleveraging a capital allocation priority. In my June 13, 2023 post, in which I disclose a new NDAQ position, I state: I do not like the degree of [...]
I last reviewed West Pharmaceutical (WST) in this July 27, 2024 post in which my Final Thoughts included: I am looking to increase my exposure in great companies that appear to have fallen out of favor. WST certainly falls in this group! WST's business remains fundamentally sound and it is still the industry leader. Despite [...]